What 7 Analyst Ratings Have To Say About Health Catalyst
What 7 Analyst Ratings Have To Say About Health Catalyst
7位分析师评级对健康催化剂有何看法
7 analysts have shared their evaluations of Health Catalyst (NASDAQ:HCAT) during the recent three months, expressing a mix of bullish and bearish perspectives.
近三个月来，7位分析师分享了他们对Health Catalyst（纳斯达克股票代码：HCAT）的评估，他们表达了看涨和看跌的观点。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
下表概述了他们最近的评级，简要介绍了过去30天中不断变化的情绪，并将其与前几个月进行了比较。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $13.14, a high estimate of $16.00, and a low estimate of $10.00. This current average reflects an increase of 1.08% from the previous average price target of $13.00.
分析师评估的12个月目标股价揭示了进一步的见解，平均目标价为13.14美元，最高估计为16.00美元，低估值为10.00美元。目前的平均价格比之前的平均目标价13.00美元上涨了1.08％。
Decoding Analyst Ratings: A Detailed Look
解码分析师评级：详细介绍
A clear picture of Health Catalyst's perception...
通过对分析师近期...
登录免费看全文
登录/注册